Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1956 1
1957 1
1958 2
1960 2
1961 1
1994 1
1995 1
1996 9
1997 21
1998 16
1999 20
2000 31
2001 44
2002 66
2003 74
2004 77
2005 96
2006 83
2007 89
2008 85
2009 94
2010 91
2011 95
2012 82
2013 87
2014 90
2015 72
2016 62
2017 69
2018 50
2019 27
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,387 results
Results by year
Filters applied: . Clear all
Page 1
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Mehta RS, et al. N Engl J Med 2019 - Clinical Trial. PMID 30917258 Free PMC article.
METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. ...Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant. CONCLUSIONS: The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. ...
METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was strati …
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, et al. Lancet 2016 - Clinical Trial. PMID 27908454
Of these, 462 patients were randomised (230 to receive fulvestrant and 232 to receive anastrozole). Progression-free survival was significantly longer in the fulvestrant group than in the anastrozole group (hazard ratio [HR] 0·797, 95% CI 0·637-0·999, p=0·0486). ...The most common adverse events were arthralgia (38 [17%] in the fulvestrant group vs 24 [10%] in the anastrozole group) and hot flushes (26 [11%] in the fulvestrant group vs 24 [10%] in the anastrozole group). 16 (7%) of 228 patients in in the fulvestrant group and 11 (5%) of 232 patients in the anastrozole group discontinued because of adverse events. ...
Of these, 462 patients were randomised (230 to receive fulvestrant and 232 to receive anastrozole). Progression-free survival was sig …
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz MP, et al. J Clin Oncol 2017 - Clinical Trial. PMID 28968163
Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. ...
Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, d …
Combination anastrozole and fulvestrant in metastatic breast cancer.
Mehta RS, et al. N Engl J Med 2012 - Clinical Trial. PMID 22853014 Free PMC article.
BACKGROUND: The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. ...CONCLUSIONS: The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard. ...
BACKGROUND: The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estroge …
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J, et al. Lancet 2014 - Clinical Trial. PMID 24333009 Free article.
FINDINGS: 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0-7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32-0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). ...
FINDINGS: 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3· …
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG, et al. Lancet 2016 - Clinical Trial. PMID 26686957 Free PMC article.
We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy. ...In total, 212 breast cancer-free interval events occurred: 122 in the tamoxifen group and 90 in the anastrozole group (HR 0·73 [95% CI 0·56-0·96], p=0·0234). ...
We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ under …
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Ma CX, et al. Clin Cancer Res 2017 - Clinical Trial. PMID 28270497 Free PMC article.
Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. ...The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P < 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. ...
Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 1
Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation.
Regenthal R, et al. Drug Des Devel Ther 2018. PMID 30464397 Free PMC article.
In contrast, a sustained-release system for the local application of anastrozole should minimize these serious adverse drug reactions. ...In vitro continuous anastrozole release profiles were studied in Franz diffusion cells. In vivo, consecutive drug plasma kinetics from the final anastrozole transdermal system was tested in beagle dogs. ...
In contrast, a sustained-release system for the local application of anastrozole should minimize these serious adverse drug reactions …
Effects of psoralen on the pharmacokinetics of anastrozole in rats.
Zhang Y, et al. Pharm Biol 2018. PMID 30345900 Free PMC article.
CONTEXT: Psoralen and anastrozole are always used together for breast cancer patients in Chinese clinics. OBJECTIVE: This study investigates the effects of psoralen on the pharmacokinetics of anastrozole in rats and its potential mechanism. ...The plasma concentration of anastrozole was determined using a sensitive and reliable LC-MS/MS method. Additionally, the effects of psoralen on the intestine transport and metabolic stability of anastrozole (1 μM) were investigated using a Caco-2 cell transwell model and rat liver microsome incubation systems. ...
CONTEXT: Psoralen and anastrozole are always used together for breast cancer patients in Chinese clinics. OBJECTIVE: This study inves …
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, et al. Lancet Oncol 2018 - Clinical Trial. PMID 29482983
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. ...Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). ...
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowl …
1,387 results
Jump to page
Feedback